| __timestamp | Catalyst Pharmaceuticals, Inc. | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 72429000 |
| Thursday, January 1, 2015 | 8597010 | 78634000 |
| Friday, January 1, 2016 | 7910260 | 75374000 |
| Sunday, January 1, 2017 | 7304399 | 92157000 |
| Monday, January 1, 2018 | 15875961 | 93326000 |
| Tuesday, January 1, 2019 | 36881187 | 103132000 |
| Wednesday, January 1, 2020 | 44233754 | 110171000 |
| Friday, January 1, 2021 | 49628000 | 218817000 |
| Saturday, January 1, 2022 | 58183000 | 233827000 |
| Sunday, January 1, 2023 | 133710000 | 267194000 |
Infusing magic into the data realm
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Lantheus Holdings, Inc. and Catalyst Pharmaceuticals, Inc. have demonstrated contrasting approaches to SG&A efficiency.
From 2014 to 2023, Lantheus Holdings consistently reported higher SG&A expenses, peaking at approximately 267 million in 2023, a 270% increase from 2014. In contrast, Catalyst Pharmaceuticals showed a more volatile trend, with a significant surge in 2023, reaching 134 million, a staggering 2900% increase from 2014.
This divergence highlights Lantheus's steady growth strategy versus Catalyst's aggressive expansion. Investors and analysts should consider these trends when evaluating the companies' operational efficiencies and long-term strategies. Understanding these dynamics can provide valuable insights into their financial health and market positioning.
AstraZeneca PLC or Lantheus Holdings, Inc.: Who Manages SG&A Costs Better?
Sarepta Therapeutics, Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Exelixis, Inc. or Lantheus Holdings, Inc.: Who Manages SG&A Costs Better?
Ascendis Pharma A/S and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Lantheus Holdings, Inc. and Veracyte, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs ImmunityBio, Inc.
Operational Costs Compared: SG&A Analysis of Lantheus Holdings, Inc. and Ligand Pharmaceuticals Incorporated
Lantheus Holdings, Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
Xenon Pharmaceuticals Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Galapagos NV Trends and Insights
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Xencor, Inc. Trends and Insights